IVIS LUMINA II XR FOR OPTICAL IMAGING OF RADIOPHARMACEUTICALS

描述(由申请人提供)：在过去的十年中，生物发光报告系统的使用在研究应用中呈指数级增长。因此，生物发光成像(BLI)已经成为华盛顿大学和世界各地分子成像不可或缺的组成部分。在成像研究实验室中，使用多种成像方式来解决生物学问题现在是司空见惯的。在Bli的新转折中，Robertson等人。(PHYS Med Biol 2009)显示，IVIS 100和200 BLI扫描仪(现已分别被IVIS Lumina和Spectrum取代)可以一致地检测到来自18F和13N核素的切伦科夫光信号。当带电粒子以超过光速的速度通过绝缘介质时，就会产生切伦科夫辐射。切伦科夫辐射是在从近紫外光到可见光的连续光谱中产生的，其分布与波长的斯奎尔成反比。切伦科夫发光成像(CLI)被描述为用发射正电子或β-的放射性药物对小鼠进行活体成像，并在检测皮下肿瘤植入物方面与18FDG PET显示出良好的相关性。另一组研究人员(Liu等人，PLoS One 2010)独立地用额外的正电子和减去β发射体的方法验证了CLI。我们建议购买IVIS Lumina II XR(卡利珀生命科学公司)，这是一种能够检测发光、荧光和X射线发射的新一代分子成像工具。伴随着x射线成像和生物发光的引入，通过将生物发光信号放在解剖学的背景下，提供了额外的分辨率。我们计划将IVIS Lumina II XR的用途分为三大类：1)涉及CLI的项目；2)涉及BLI和荧光成像的项目，用于监测具有β发射的放射性药物的靶向放射治疗；以及3)传统的BLI实验。CLI应用将集中于开发新型PET放射性药物的高通量评估。华盛顿大学拥有理想的师资和资源，可以更充分地开发新的CLI技术。我们有8名由美国国立卫生研究院资助的用户开发放射性药物和多模式显像剂，其中一位(戴博士)开发PET/光学仪器。吴的现有师资、设施和资源，加上强有力的机构支持，将确保IVIS Lumina II XR得到进一步利用和发展，成为一项新的尖端技术，这将使吴作为一所大学以及整个成像社区受益。 公共卫生相关性：分子成像是一门涉及分子过程的非侵入性成像的科学。我们建议购买IVIS Lumina II XR(卡利珀生命科学公司)，这是一种能够检测发光、荧光和X射线发射的新一代分子成像工具。华盛顿大学将主要将该仪器用于“切伦科夫发光成像”，这是一项专为高通量放射性药物开发而设计的尖端技术。

DESCRIPTION (provided by applicant): Throughout the last decade, the use of bioluminescence reporter systems has seen an exponential growth in research applications. As a result, bioluminescence imaging (BLI) has become an indispensible component of molecular imaging at Washington University and throughout the world. The use of multiple imaging modalities to address biological questions is now commonplace in imaging research laboratories. In a new twist on BLI, Robertson et al. (Phys Med Biol 2009) showed that the IVIS 100 and 200 BLI scanners (which have now been replaced by the IVIS Lumina and Spectrum, respectively) could consistently detect a Cerenkov light signal from 18F and 13N nuclides. Cerenkov radiation is produced when a charged particle travels with a velocity that exceeds the speed of light through an insulating medium. Cerenkov radiation is produced in a continuous spectrum from the near ultraviolet through the visible spectrum, distributed inversely proportional to the squire of the wavelength. "Cerenkov luminescence imaging" (CLI) was described for in vivo imaging of mice with radiopharmaceuticals that emit either positron or beta minus, and demonstrated a good correlation with 18FDG PET in detecting a subcutaneous tumor implant. Independently, another group of researchers (Liu et al, PLoS One 2010) validated CLI with additional positron and beta minus emitters. We propose the purchase of an IVIS Lumina II XR (Caliper Life Sciences, Inc.), a new generation molecular imaging tool capable of detecting luminescence, fluorescence, and x-ray emissions. The introduction of concomitant x-ray imaging with bioluminescence provides an additional degree of resolution by putting the bioluminescence signal in anatomical context. Our intended use of the IVIS Lumina II XR can be separated into three general categories: 1) projects that involve CLI; 2) projects that involve BLI and fluorescence imaging for monitoring targeted radiotherapy with beta emitting radiopharmaceuticals; and 3) traditional BLI experiments. The CLI applications will focus on developing high throughput assessment of novel PET radiopharmaceuticals. Washington University has the ideal faculty and resources to more fully develop the new CLI technology. We have 8 NIH-funded users developing radiopharmaceuticals and multimodality imaging agents, and one of them (Dr. Tai) develops PET/optical instrumentation. The existing faculty, facilities and resources at WU, together with strong institutional support, will ensure that the IVIS Lumina II XR will be utilized and developed further for a new, cutting-edge technology, which will benefit WU as a university, as well as the imaging community as a whole. Public Health Relevance: Molecular imaging is a science involving non-invasive imaging of molecular processes. We propose to purchase an IVIS Lumina II XR (Caliper Life Sciences, Inc.), a new generation molecular imaging tool capable of detecting luminescence, fluorescence, and x-ray emissions. Washington University will use the instrument primarily for "Cerenkov luminescence imaging" a cutting-edge technology designed for high throughput radiopharmaceutical development.